FAQ on Izotropic Corporation's IzoView Breast CT Imaging System
Summary
What is the IzoView Breast CT Imaging System?
The IzoView Breast CT Imaging System is a medical device developed by Izotropic Corporation for breast cancer detection and treatment, offering true 3D, ultra-high-resolution imaging without the need for breast compression.
How does IzoView compare to current breast imaging technologies?
IzoView offers 100x greater spatial resolution than MRI at a lower cost and with shorter scan times, designed to bridge the gap between digital breast tomosynthesis and MRI, especially beneficial for women with dense breast tissue.
Why is the IzoView Breast CT Imaging System significant?
It aims to improve screening, diagnosis, and treatment planning for breast cancer by providing high-resolution imaging without compression, which could lead to earlier and more accurate detection.
Who developed the IzoView Breast CT Imaging System?
Izotropic Corporation developed the IzoView system under a global license from UC Davis.
Where can I find more information about Izotropic Corporation?
More information can be found on Izotropic Corporation’s website at https://izocorp.com/ and by reviewing its profile on SEDAR at sedarplus.ca.
What are the benefits of the IzoView Breast CT Imaging System?
Benefits include true 3D imaging, ultra-high resolution, no breast compression, lower cost than MRI, and shorter scan times, aiming to enhance breast cancer detection and treatment planning.
How can I view the full press release about IzoView?
The full press release can be viewed at https://ibn.fm/NbLB2.
What is TechMediaWire?
TechMediaWire is a specialized communications platform focusing on pioneering public and private companies driving the future of technology, part of the Dynamic Brand Portfolio @ IBN.
How can I receive SMS alerts from TechMediaWire?
To receive SMS alerts from TechMediaWire, text ‘TECH’ to 888-902-4192 (U.S. Mobile Phones Only).
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 124785